OptiNose, Inc. (OPTN)
9.60
-0.11 (-1.13%)
Inactive · Last trade price
on May 20, 2025
OptiNose Revenue
OptiNose had revenue of $18.51M in the quarter ending March 31, 2025, with 24.40% growth. This brings the company's revenue in the last twelve months to $81.86M, up 10.58% year-over-year. In the year 2024, OptiNose had annual revenue of $78.23M with 10.20% growth.
Revenue (ttm)
$81.86M
Revenue Growth
+10.58%
P/S Ratio
1.31
Revenue / Employee
$639,500
Employees
128
Market Cap
97.22M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 78.23M | 7.24M | 10.20% |
Dec 31, 2023 | 70.99M | -5.29M | -6.93% |
Dec 31, 2022 | 76.28M | 1.62M | 2.18% |
Dec 31, 2021 | 74.65M | 25.54M | 51.99% |
Dec 31, 2020 | 49.12M | 14.49M | 41.83% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOPTN News
- 5 weeks ago - OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN - Business Wire
- 2 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders - GlobeNewsWire
- 2 months ago - Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call - GlobeNewsWire
- 2 months ago - Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS) - GlobeNewsWire
- 5 months ago - Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million - GlobeNewsWire
- 5 months ago - Optinose Announces 1-for-15 Reverse Stock Split - GlobeNewsWire
- 6 months ago - Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 7 months ago - OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript - Seeking Alpha